Mackenzie Financial Corp Has $1.51 Million Holdings in Option Care Health, Inc. (NASDAQ:OPCH)

Mackenzie Financial Corp increased its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 9.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 44,805 shares of the company’s stock after purchasing an additional 4,024 shares during the period. Mackenzie Financial Corp’s holdings in Option Care Health were worth $1,509,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC boosted its stake in Option Care Health by 63.3% in the 4th quarter. Mutual of America Capital Management LLC now owns 190,684 shares of the company’s stock worth $6,424,000 after purchasing an additional 73,938 shares during the period. Wellington Management Group LLP boosted its stake in shares of Option Care Health by 15.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,896,392 shares of the company’s stock worth $93,698,000 after buying an additional 397,627 shares during the last quarter. Ontario Teachers Pension Plan Board acquired a new position in shares of Option Care Health during the 3rd quarter worth about $546,000. Van ECK Associates Corp boosted its stake in shares of Option Care Health by 244.2% during the 3rd quarter. Van ECK Associates Corp now owns 34,291 shares of the company’s stock worth $1,109,000 after buying an additional 24,328 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new position in shares of Option Care Health during the 3rd quarter worth about $2,816,000. 98.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Option Care Health

In related news, Director Harry M. Jansen Kraemer, Jr. purchased 35,000 shares of the stock in a transaction on Monday, February 26th. The shares were purchased at an average cost of $31.55 per share, with a total value of $1,104,250.00. Following the acquisition, the director now directly owns 269,528 shares in the company, valued at $8,503,608.40. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.64% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on OPCH shares. Barrington Research restated an “outperform” rating and set a $38.00 price objective on shares of Option Care Health in a research note on Wednesday. Jefferies Financial Group increased their price objective on shares of Option Care Health from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, March 4th.

Option Care Health Stock Down 2.2 %

Shares of OPCH stock opened at $29.93 on Thursday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.33 and a current ratio of 1.77. The firm’s 50-day moving average is $32.13 and its 200-day moving average is $31.52. The stock has a market cap of $5.20 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 1.73 and a beta of 1.22. Option Care Health, Inc. has a 52-week low of $24.23 and a 52-week high of $35.74.

Option Care Health (NASDAQ:OPCH) last issued its earnings results on Tuesday, April 23rd. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. The company had revenue of $1.15 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Option Care Health had a net margin of 6.21% and a return on equity of 18.78%. Option Care Health’s quarterly revenue was up 12.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.21 EPS. Sell-side analysts predict that Option Care Health, Inc. will post 1.13 EPS for the current year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.